Alzheimer’s Research Antibodies
Alzheimer’s research antibodies play a significant role in helping scientists find solutions to this disease and other dementias that affect 47 million people worldwide and 5.3 million Americans, numbers that are expected to triple by 2050, according to the Alzheimer’s Association. As the baby boomers age, 28 million are expected to develop this disease, with costs rising to nearly a quarter of all Medicare spending in the United States.
Since Dr. Aloysius Alzheimer first described the disease in 1906, scientists have made remarkable progress in understanding how this disease affects the brain. Over a decade later, breakthroughs in understanding and treatments are providing hope for people with Alzheimer’s disease.
These ImmunoStar antibodies have proven records in Alzheimer’s research. Search our Publication’s database with the keyword “Alzheimer’s” to find hundreds of publications referencing these antibodies. See our customer Testimonials for comments from neuroscientists extolling the results and service they rely on from ImmunoStar. Our antibodies are stable, high-titer, and consistent from lot-to-lot to ensure successful staining at an excellent value.
ImmunoStar Antibodies Proven for Alzheimer’s Research
Neuropeptide Y (NPY) is a member of a regulatory peptide family and has a marked sequence homology with pancreatic polypeptide (PP) and peptide YY (PYY), which are other members of the family. NPY is widely expressed in the nervous system and has been shown to be differentially expressed in inhibitory interneurons in the hippocampus in degenerative disease, as a powerful vasoconstrictor in the periphery, and increased expression of NPY in the hypothalamus correlates with food intake.
Tyrosine Hydroxylase #22941
The ImmunoStar monoclonal Tyrosine Hydroxylase antiserum was quality control tested using standard immunohistochemical methods. The antiserum demonstrates strongly positive labeling of rat catecholamine neuron systems using indirect immunofluorescent and biotin/avidin-HRP techniques. Recommended primary dilution is 1/4000 – 1/8000 with the biotin/avidin-HRP technique. This antibody has been used successfully for IHC, ICC, FC, and IP.
5-HT (Serotonin) Rabbit #20080
The ImmunoStar serotonin antiserum was quality control tested using standard immunohistochemical methods. The antiserum demonstrates strongly positive labeling of rat hypothalamus, raphe nuclei and spinal cord using indirect immunofluorescent and biotin/avidin-HRP techniques.
The antibody has a proven strong Biotin-Streptavidin/HRP staining at a 1/4000-1/6000 dilution in rat amygdala, cortex, and suprachiasmatic nucleus.
These ImmunoStar antibodies are also recommended for Alzheimer’s research. Search our Publications database by their name, number, or keyword “Alzheimer’s.”
5-HT (Serotonin) Transporter #24330
The antiserum demonstrates strongly positive labeling of rat raphe nuclei, hypothalamus, cortex and spinal cord using indirect immunofluorescent and biotin/avidin-HRP techniques.
The ImmunoStar antiserum was quality control tested using standard immunohistochemical methods. The antiserum demonstrates strongly positive labeling of rat median eminence using indirect immunofluorescent and biotin/avidin-HRP techniques.
The monoclonal antibody produces strong labeling of glutamate at dilutions of 1/2,000 – 1/4,000 using biotin-streptavidin/HRP technique.
Methionine Enkephalin #20065
The antibody has a proven strong biotin-streptavidin/HRP staining at 1/1,000-1/1,200 dilution in rat globus pallidus and amygdala.
Somatostatin 28 #20089
The antibody has a proven Biotin-Streptavidin/HRP staining at a 1/1000-1/2000 dilution in rat hypothalamus/median eminence.
for Alzheimer’s Research
The latest news, discoveries, and developments in diagnostics and treatments for Alzheimer’s disease and related disorders.